Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raghunandan R

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Brain Informatics|October 5, 2021
EEG-based human emotion recognition using entropy as a feature extraction measurePragati Patel, Raghunandan R, Ramesh Naidu Annavarapu
British Journal of Haematology|October 8, 2024
Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3-dependent mechanism in vitro and in vivoLin Li, Xiaoyan Hu, Jewel Nkwocha, et al.
Haematologica|December 5, 2024
Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myelomaRyan T Bishop, Tao Li, Praneeth Sudalagunta, et al.
Blood Advances|May 2, 2022
Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myelomaLauren C Peres, Christelle M Colin-Leitzinger, Mingxiang Teng, et al.
Research Square|August 20, 2025
Unc-51 Like Kinase 3 (ULK3) is essential for autophagy and cell survival in multiple myelomaMarilena Tauro, Tao Li, Praneeth R Sudalagunta, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Brain Informatics|October 5, 2021
EEG-based human emotion recognition using entropy as a feature extraction measurePragati Patel, Raghunandan R, Ramesh Naidu Annavarapu
British Journal of Haematology|October 8, 2024
Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3-dependent mechanism in vitro and in vivoLin Li, Xiaoyan Hu, Jewel Nkwocha, et al.
Haematologica|December 5, 2024
Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed/refractory multiple myelomaRyan T Bishop, Tao Li, Praneeth Sudalagunta, et al.
Blood Advances|May 2, 2022
Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myelomaLauren C Peres, Christelle M Colin-Leitzinger, Mingxiang Teng, et al.
Research Square|August 20, 2025
Unc-51 Like Kinase 3 (ULK3) is essential for autophagy and cell survival in multiple myelomaMarilena Tauro, Tao Li, Praneeth R Sudalagunta, et al.
Pageof 1